QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 CelsionMereo BioPharma GroupMerrimack PharmaceuticalsVascular BiogenicsNeuroBo Pharmaceuticals
SymbolNASDAQ:CLSNNASDAQ:MREONASDAQ:MACKNASDAQ:VBLTNASDAQ:NRBO
Price Information
Current Price$2.14$4.43$7.16$1.97$4.68
52 Week RangeHoldN/AN/ABuyBuy
MarketRank™
Overall Score1.30.70.91.31.7
Analysis Score3.00.00.03.53.5
Community Score2.72.22.92.43.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.70.00.8
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationHoldN/AN/ABuyBuy
Consensus Price Target$4.00N/AN/A$4.13$16.00
% Upside from Price Target86.92% upsideN/AN/A109.39% upside241.88% upside
Trade Information
Market Cap$80.08 million$110.31 million$95.80 million$94.36 million$92.06 million
Beta2.421.692.551.170.69
Average Volume27,505,6782,421,334118,7471,435,346584,565
Sales & Book Value
Annual Revenue$500,000.00N/AN/A$560,000.00N/A
Price / Sales160.15N/AN/A168.49N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.63 per share$2.06 per share$1.30 per share$1.00 per share$0.79 per share
Price / Book3.40N/AN/A1.97N/A
Profitability
Net Income$-16,850,000.00$-44,490,000.00$-17,330,000.00$-19,460,000.00$-21,310,000.00
EPS($0.91)($2.49)N/A($0.54)($4.08)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4,315.00%N/AN/A-2,692.41%N/A
Return on Equity (ROE)-104.32%N/A-14.94%-61.77%-224.41%
Return on Assets (ROA)-47.65%N/A-12.96%-47.23%-171.64%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.25%0.60%N/AN/AN/A
Current Ratio3.67%2.99%8.42%5.16%3.57%
Quick Ratio3.67%N/A8.42%5.16%3.57%
Ownership Information
Institutional Ownership Percentage13.73%62.14%52.25%4.50%4.50%
Insider Ownership Percentage20.49%N/A21.60%N/A56.10%
Miscellaneous
Employees2950273812
Shares Outstanding37.42 million24.90 million13.38 million47.90 million19.67 million
Next Earnings Date3/24/2021 (Estimated)6/15/2021 (Estimated)3/11/2021 (Estimated)3/18/2021 (Estimated)3/29/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.